Michael Haffner
Genomic rearrangements that lead to the juxtaposition of two non-neighbor genes such as TMPRSS2 and ERG are some of the most common alterations in prostate cancer. The origin of these...Read More
David Olmos
BRCA is a gene that mediates DNA repair. Mutations in BRCA cause genomic instability and greatly enhance risks for developing breast, ovarian, and other cancers. Dr. David Olmos has found...Read More
Andrew Goldstein
The first medical treatment for metastatic prostate cancer is Androgen Deprivation Therapy (ADT). Unfortunately, nearly 100% of patients become refractory to this treatment and their cancer progresses to androgen-independent, castration-resistant...Read More
Owen Witte, MD
Target identification Combining In Vivo Tissue Transformation with Multi-parameter Profiling and “Surprisal Analysis” The goal of this highly creative proposal is to search for and discover new pathways and therapeutic...Read More
Himisha Beltran
Dr. Beltran’s research will help define the genetic basis of a rare and aggressive form of prostate cancer called neuroendocrine (small cell) prostate cancer (NEPC). Patients diagnosed with NEPC often...Read More
Matthew Cooperberg
The landscape of therapeutic options for men with advanced prostate cancer is evolving at an unprecedented rate. Multiple novel agents extend survival and quality of life via independent, non-overlapping mechanisms;...Read More
Todd Morgan, MD
Todd M. Morgan, M.D. is a urological surgeon specializing in the treatment of genitourinary malignancies. Dr. Morgan is a translational surgeon-scientist, and his research spans the spectrum from preclinical laboratory-based...Read More
Marianne Sadar, PhD
Niphatenones a Completely New Class of Androgen Receptor Antagonist Dr. Sadar has discovered and is developing compounds derived from undersea plant life for development of new treatments for metastatic prostate...Read More
Rohit Malik
Therapies targeting the androgen receptor (AR) are the primary treatment approach for metastatic prostate cancer. Patients eventually progress to an aggressive drug-resistant disease state termed castrate-resistant prostate cancer (CRPC). Dr....Read More